NZ701601A - Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy - Google Patents
Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapyInfo
- Publication number
- NZ701601A NZ701601A NZ701601A NZ70160113A NZ701601A NZ 701601 A NZ701601 A NZ 701601A NZ 701601 A NZ701601 A NZ 701601A NZ 70160113 A NZ70160113 A NZ 70160113A NZ 701601 A NZ701601 A NZ 701601A
- Authority
- NZ
- New Zealand
- Prior art keywords
- gcc
- antibody molecules
- targeted therapy
- methods
- antibodies
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639376P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038542 WO2013163633A1 (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ701601A true NZ701601A (en) | 2016-09-30 |
Family
ID=49477498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ701601A NZ701601A (en) | 2012-04-27 | 2013-04-27 | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy |
Country Status (41)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2774032C (en) | 2009-10-23 | 2019-03-26 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
| US20160264663A1 (en) * | 2013-10-21 | 2016-09-15 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| WO2015123574A1 (en) | 2014-02-14 | 2015-08-20 | The Board Of Trustees Of The University Of Arkansas | Acetaminophen protein adducts and methods of use thereof |
| JP6785239B2 (ja) | 2014-12-03 | 2020-11-18 | バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ | 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物 |
| CA3000242A1 (en) | 2015-10-01 | 2017-04-06 | The Centre For Drug Research And Development | Anti-podocalyxin antibodies and methods of using the same |
| US11473081B2 (en) | 2016-12-12 | 2022-10-18 | xCella Biosciences, Inc. | Methods and systems for screening using microcapillary arrays |
| KR102080887B1 (ko) * | 2017-11-07 | 2020-02-24 | 고려대학교 산학협력단 | Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물 |
| CN111448569B (zh) * | 2017-12-06 | 2023-09-26 | 文塔纳医疗系统公司 | 存储和检索数字病理学分析结果的方法 |
| US11568657B2 (en) | 2017-12-06 | 2023-01-31 | Ventana Medical Systems, Inc. | Method of storing and retrieving digital pathology analysis results |
| PL3846788T3 (pl) * | 2018-09-05 | 2026-02-23 | Universiteit Van Amsterdam | Inhibitory pde11 do zastosowania w leczeniu choroby parkinsona |
| WO2021205325A1 (en) * | 2020-04-08 | 2021-10-14 | Pfizer Inc. | Anti-gucy2c antibodies and uses thereof |
| IL296519A (en) * | 2020-06-02 | 2022-11-01 | Teijin Pharma Ltd | Anti-igf-1 receptor humanized antibody |
| WO2022127871A1 (en) * | 2020-12-17 | 2022-06-23 | Parasol Biotech Ltd. | Gucy2c binding molecules and uses thereof |
| MX2023011862A (es) * | 2021-04-07 | 2024-01-08 | Lg Chemical Ltd | Polipeptido de union a gucy2c y usos del mismo. |
| KR20250075590A (ko) * | 2022-09-28 | 2025-05-28 | 레전드 바이오테크 아일랜드 리미티드 | Gcc를 표적으로 하는 항체 및 키메라 항원 수용체 및 이의 사용 방법 |
| KR20250099224A (ko) | 2022-11-01 | 2025-07-01 | 하이델베르크 파마 리서치 게엠베하 | 항-gucy2c 항체 및 이의 용도 |
| CN116535514B (zh) * | 2023-06-15 | 2024-02-02 | 上海斯丹赛生物技术有限公司 | 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用 |
| CN117069848B (zh) * | 2023-08-02 | 2025-02-28 | 武汉爱博泰克生物科技有限公司 | 抗人cd146兔单克隆抗体及其应用 |
| WO2025061149A1 (zh) * | 2023-09-21 | 2025-03-27 | 南京传奇生物科技有限公司 | 抗gcc抗体、嵌合抗原受体及其用途 |
| EP4566631A1 (en) | 2023-12-06 | 2025-06-11 | Heidelberg Pharma Research GmbH | New antibody drug conjugate as well as methods of production and uses thereof |
| CN120965861B (zh) * | 2025-10-22 | 2026-02-13 | 杭州博茵生物技术有限公司 | 一种Fc效应消除的新型骨架流式抗体及其制备方法与应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5237051A (en) | 1990-12-06 | 1993-08-17 | Vanderbilt University | Purified enterotoxin receptor protein |
| US5879656A (en) | 1993-10-26 | 1999-03-09 | Thomas Jefferson University | Methods of treating metastatic colorectal cancer with ST receptor binding compounds |
| US5601990A (en) | 1994-09-13 | 1997-02-11 | Thomas Jefferson University | Methods of diagnosing colorectal tumors and metastasis thereof |
| US5518888A (en) | 1993-10-26 | 1996-05-21 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| ATE259648T1 (de) | 1993-10-26 | 2004-03-15 | Univ Jefferson | Verbindungen die kolorektale krebszellen spezifisch binden und verfahren für ihre herstellung |
| US7097839B1 (en) | 1993-10-26 | 2006-08-29 | Thomas Jefferson University | ST receptor binding compounds and methods of using the same |
| US6455251B1 (en) | 1994-09-13 | 2002-09-24 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| CA2254082C (en) | 1996-05-03 | 2012-09-11 | Thomas Jefferson University | Metastatic colorectal cancer vaccine |
| US6602659B1 (en) | 1996-05-03 | 2003-08-05 | Thomas Jefferson University | Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof |
| US6120995A (en) | 1997-08-07 | 2000-09-19 | Thomas Jefferson University | Compositions that specifically bind to colorectal cancer cells and methods of using the same |
| US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
| US8092514B1 (en) | 1998-11-16 | 2012-01-10 | Boston Scientific Scimed, Inc. | Stretchable anti-buckling coiled-sheet stent |
| US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
| ATE452989T1 (de) | 2000-03-27 | 2010-01-15 | Univ Jefferson | Zusammensetzungen und methoden zur identifizierung von krebszellen |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| WO2002072600A2 (en) | 2001-01-26 | 2002-09-19 | Inhibitex, Inc. | Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections |
| DE60233040D1 (de) | 2001-03-29 | 2009-09-03 | Synergy Pharmaceuticals Inc | Guanylat-cyclase-rezeptor-agonisten zur behandlung von gewebeentzündung und karzinogenese |
| MXPA03009390A (es) | 2001-04-13 | 2004-01-29 | Biogen Inc | Anticuerpos para integrina vla-1. |
| AU2002361886A1 (en) | 2001-12-28 | 2003-07-24 | Abgenix, Inc. | Antibodies against the muc18 antigen |
| US20040110933A1 (en) | 2002-09-13 | 2004-06-10 | Dyax Corporation | CD44-binding ligands |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2004071436A2 (en) | 2003-02-10 | 2004-08-26 | Thomas Jefferson University | The use of gcc ligands |
| JP4889493B2 (ja) | 2003-05-14 | 2012-03-07 | ドマンティス リミテッド | ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法 |
| US7871610B2 (en) | 2003-08-12 | 2011-01-18 | Dyax Corp. | Antibodies to Tie1 ectodomain |
| EP1781339B1 (en) | 2004-06-25 | 2013-12-25 | Thomas Jefferson University | Guanylyl cyclase C ligands |
| WO2006068953A2 (en) | 2004-12-21 | 2006-06-29 | Astrazeneca Ab | Antibodies directed to angiopoietin-2 and uses thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
| KR101588276B1 (ko) * | 2007-08-10 | 2016-01-26 | 센토코 오르토 바이오테크 인코포레이티드 | 질환 표시자로서의 면역글로불린 절단 단편, 및 그의 검출 및 결합을 위한 조성물 |
| KR101709488B1 (ko) | 2007-08-10 | 2017-02-24 | 리제너론 파아마슈티컬스, 인크. | 인간 신경성장인자에 대한 고친화성 인간 항체 |
| AU2008334070B2 (en) * | 2007-11-30 | 2015-04-16 | Genentech, Inc. | VEGF polymorphisms and anti-angiogenesis therapy |
| US20110195415A1 (en) | 2008-05-13 | 2011-08-11 | Thomas Jefferson University | Guanylyl cyclase c qrt-pcr |
| ES2559840T3 (es) | 2008-06-04 | 2016-02-16 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
| US9090695B2 (en) | 2008-12-03 | 2015-07-28 | Morphosys Ag | Antibodies for guanylyl cyclase receptors |
| DK2881402T3 (en) * | 2009-02-12 | 2017-08-28 | Cell Signaling Technology Inc | Mutant ROS expression in human liver cancer |
| US20110306055A1 (en) | 2009-02-25 | 2011-12-15 | Diagnocure Inc. | Method for Detecting Metastasis of GI Cancer |
| JPWO2010104035A1 (ja) * | 2009-03-12 | 2012-09-13 | 学校法人近畿大学 | 非小細胞肺癌に対する化学療法の治療効果予測方法 |
| CA2801729A1 (en) | 2009-06-15 | 2010-12-23 | Thomas Jefferson University | Compositions for and methods of activating guanylyl cyclase c |
| JP5955771B2 (ja) | 2009-10-22 | 2016-07-20 | トーマス・ジェファーソン・ユニバーシティＴｈｏｍａｓ Ｊｅｆｆｅｒｓｏｎ Ｕｎｉｖｅｒｓｉｔｙ | 細胞ベースの抗癌組成物ならびに当該物の製造方法および使用方法 |
| CA2774032C (en) * | 2009-10-23 | 2019-03-26 | Millennium Pharmaceuticals, Inc. | Anti-gcc antibody molecules and related compositions and methods |
| JP2013534515A (ja) * | 2010-06-01 | 2013-09-05 | モナシュ ユニバーシティ | プロセシングされていない受容体型チロシンキナーゼｃ−ＭＥＴに対する抗体 |
| JP2013539460A (ja) * | 2010-08-13 | 2013-10-24 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ベバシズマブ併用療法のためのバイオマーカーとしてのニューロピリン |
| US20150086481A1 (en) | 2011-07-28 | 2015-03-26 | Memorial Sloan-Kettering Cancer Center | Diagnosis and treatment of parkinson's disease |
| US9156915B2 (en) | 2012-04-26 | 2015-10-13 | Thomas Jefferson University | Anti-GCC antibody molecules |
| KR20150122730A (ko) * | 2013-02-28 | 2015-11-02 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 암의 치료에서 항-gcc 항체-약물 콘주게이트 및 dna 손상 제제의 투여 |
-
2013
- 2013-04-27 EA EA201491977A patent/EA034689B1/ru unknown
- 2013-04-27 KR KR1020147032890A patent/KR102046435B1/ko not_active Expired - Fee Related
- 2013-04-27 CN CN201380033309.4A patent/CN104395470B/zh active Active
- 2013-04-27 AU AU2013251312A patent/AU2013251312B2/en not_active Ceased
- 2013-04-27 SM SM20190536T patent/SMT201900536T1/it unknown
- 2013-04-27 US US13/872,080 patent/US9000129B2/en active Active
- 2013-04-27 GE GEAP201313644A patent/GEP201706737B/en unknown
- 2013-04-27 SA SA113340502A patent/SA113340502B1/ar unknown
- 2013-04-27 WO PCT/US2013/038542 patent/WO2013163633A1/en not_active Ceased
- 2013-04-27 PE PE2014001908A patent/PE20142322A1/es active IP Right Grant
- 2013-04-27 MX MX2014013081A patent/MX362020B/es active IP Right Grant
- 2013-04-27 JP JP2015509208A patent/JP6472746B2/ja active Active
- 2013-04-27 RS RSP20191239 patent/RS59370B1/sr unknown
- 2013-04-27 EP EP13782061.9A patent/EP2841575B1/en active Active
- 2013-04-27 HR HRP20191690TT patent/HRP20191690T1/hr unknown
- 2013-04-27 ME MEP-2019-257A patent/ME03560B/me unknown
- 2013-04-27 PL PL13782061T patent/PL2841575T3/pl unknown
- 2013-04-27 MY MYPI2014703176A patent/MY188442A/en unknown
- 2013-04-27 MA MA37569A patent/MA37569B1/fr unknown
- 2013-04-27 LT LTEP13782061.9T patent/LT2841575T/lt unknown
- 2013-04-27 SG SG11201406855TA patent/SG11201406855TA/en unknown
- 2013-04-27 PT PT137820619T patent/PT2841575T/pt unknown
- 2013-04-27 SI SI201331582T patent/SI2841575T1/sl unknown
- 2013-04-27 ES ES13782061T patent/ES2749181T3/es active Active
- 2013-04-27 CA CA2871614A patent/CA2871614C/en active Active
- 2013-04-27 UA UAA201412715A patent/UA117910C2/uk unknown
- 2013-04-27 NZ NZ701601A patent/NZ701601A/en not_active IP Right Cessation
- 2013-04-27 DK DK13782061.9T patent/DK2841575T3/da active
- 2013-04-27 HU HUE13782061A patent/HUE046404T2/hu unknown
- 2013-04-29 AR ARP130101458A patent/AR090884A1/es active IP Right Grant
- 2013-04-29 TW TW102115363A patent/TWI631137B/zh active
-
2014
- 2014-10-23 IL IL235307A patent/IL235307B/en active IP Right Grant
- 2014-10-23 ZA ZA2014/07723A patent/ZA201407723B/en unknown
- 2014-10-24 PH PH12014502399A patent/PH12014502399B1/en unknown
- 2014-10-24 DO DO2014000242A patent/DOP2014000242A/es unknown
- 2014-10-24 TN TN2014000454A patent/TN2014000454A1/fr unknown
- 2014-10-27 CL CL2014002911A patent/CL2014002911A1/es unknown
- 2014-10-27 CR CR20140497A patent/CR20140497A/es unknown
- 2014-11-25 EC ECIEPI201428523A patent/ECSP14028523A/es unknown
- 2014-11-26 CO CO14260074A patent/CO7280144A2/es unknown
-
2015
- 2015-02-27 US US14/634,438 patent/US9273146B1/en active Active
-
2016
- 2016-01-19 US US15/000,950 patent/US20160130344A1/en not_active Abandoned
-
2017
- 2017-04-26 JP JP2017087084A patent/JP6517267B2/ja not_active Expired - Fee Related
-
2019
- 2019-09-24 CY CY20191101005T patent/CY1122557T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502399A1 (en) | Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy | |
| WO2009085216A3 (en) | Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease | |
| BR112018005322A2 (pt) | anticorpo monoclonal ou seu fragmento de ligação a antígenos, composição farmacêutica, anticorpo monoclonal ou seu fragmento de ligação a antígenos para uso, método de tratamento de lesão de isquemia-reperfusão, método de tratamento de câncer em um paciente humano, método de avaliação da expressão de cd47 em células tumorais e/ou imunes usando um anticorpo monoclonal ou seu fragmento de ligação a antígenos | |
| CY1121392T1 (el) | Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης | |
| MX383886B (es) | Anticuerpo anti-trop-2 humano que tiene una actividad antitumoral in vivo. | |
| IL214255B (en) | Use of antibodies for preparation of medicaments for treatment of cancer associated with a tumor antigen and methods for diagnosis of cancer associated with a tumor antigen | |
| EA201291260A1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
| MX362514B (es) | Kits y ensayos de diagnostico para la deteccion del receptor 1 de folato. | |
| EP3236262A3 (en) | Surrogate functional diagnostics test for cancer | |
| WO2008103645A8 (en) | Prostate cancer and melanoma antigens | |
| CO6351751A2 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos | |
| UA106771C2 (uk) | Моноклональні антитіла до прогастрину та їх використання | |
| WO2011015333A3 (en) | Targeting of bone marrow neovasculature | |
| PH12014501164A1 (en) | Anti-cd98 antibodies and methods of use thereof | |
| CY1120063T1 (el) | Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo | |
| WO2015013508A3 (en) | Methods for diagnosing and treating immune disease | |
| EP2614375A4 (en) | COMBINATION METHOD FOR CANCER DIAGNOSIS | |
| BR112013016107A2 (pt) | molécula dimérica, método de tratamento de câncer, composição farmacêutica e kit para o diagnóstico de uma patologia ou tumor mediado(a) por upar | |
| BRPI0923652A2 (pt) | diagnóstico e tratamento de câncer usando anticorpo anti-lgr7 | |
| MX2015002749A (es) | Metodo diagnostico y terapeutico para el cancer dirigido a moleculas expresadas en celulas madre cancerosas. | |
| BR112015031950A2 (pt) | métodos para tratamento de câncer de ovário | |
| EP2844776A4 (en) | CANCER BLOOD TEST USING INSULATED BC200 RNA FROM PERIPHERAL BLOOD FOR THE DIAGNOSIS AND TREATMENT OF INVASIVE BREAST CANCER | |
| WO2012119989A3 (en) | Antibodies against cadmi for the diagnosis and treatment of cancer | |
| EA201001731A1 (ru) | Применение радиоактивно меченой молекулы, которая специфически связывается с ed-b фибронектином, в способе лечения лимфомы ходжкина | |
| TH1401006471A (th) | โมเลกุลแอนติบอดีต้าน gcc และการใช้โมเลกุลดังกล่าวเพื่อทดสอบภูมิไวรับต่อการรักษาที่มุ่งเป้าไปที่ gcc |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2018 BY COMPUTER PACKAGES INC Effective date: 20170331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2019 BY COMPUTER PACKAGES INC Effective date: 20180331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2020 BY COMPUTER PACKAGES INC Effective date: 20190402 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2021 BY COMPUTER PACKAGES INC Effective date: 20200331 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2022 BY COMPUTER PACKAGES INC Effective date: 20210330 |
|
| ASS | Change of ownership |
Owner name: TAKEDA PHARMACEUTICAL COMPANY, JP Effective date: 20211022 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2023 BY ANAQUA SERVICES Effective date: 20220322 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2024 BY ANAQUA SERVICES Effective date: 20230322 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 APR 2025 BY ANAQUA SERVICES Effective date: 20240320 |
|
| LAPS | Patent lapsed |